A culture medium for thyroid cancer organoids, its preparation method and uses; a method for culturing thyroid cancer organoids.
By optimizing the culture medium and methods for thyroid cancer organoids, the problems of imperfect culture medium composition and low efficiency in existing technologies have been solved, achieving efficient and stable thyroid cancer organoid culture. This is applicable to different pathological types and low cell count samples, promoting thyroid cancer research and personalized treatment.
Patent Information
- Application Number
- CN202611475453.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-21
- Publication Date
- 2026-11-10
AI Technical Summary
Existing methods for culturing thyroid cancer organoids suffer from problems such as imperfect culture medium composition, low culture efficiency, insufficient standardization of culture methods, and inability to be applied to different pathological types and low cell mass samples, resulting in slow cell growth, abnormal differentiation, and unstable culture.
A specific composition of thyroid cancer organoid culture medium, including basal medium DMEM/F12 and specific additives HEPES, GlutaMAX, P/S, N2, B-27, EGF, FGF basic, FGF10, HGF, IGF, Wnt3a, R-spondin-1, A83-01, GSK429286A, Noggin, BIRB 796, nicotinamide and N-acetyl-L-cysteine, Monensin, P5091, A35, combined with optimized culture methods such as digestion, incubation conditions and medium replacement frequency, was used to promote cell proliferation and self-assembly.
It improves the culture efficiency and stability of thyroid cancer organoids, is suitable for various pathological types and low cell count samples, has a short culture cycle, high cell activity, and produces dense thyroid cancer organoid spheroids with a high spheroidization rate, making it suitable for mechanism research and drug screening of thyroid cancer.
Smart Images

Figure CN123063339A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to a culture medium for thyroid cancer organoids, its preparation method and uses, and a method for culturing thyroid cancer organoids. Background Technology
[0002] Thyroid cancer is the most common malignant tumor of the endocrine system, and its incidence is increasing globally. Although most thyroid cancer patients have a good prognosis after surgery and radioactive iodine therapy, existing treatments are less effective for some aggressive subtypes that are resistant to traditional therapies, such as undifferentiated and poorly differentiated carcinomas. Therefore, in-depth research into the mechanisms of thyroid cancer development and progression, and the exploration of new treatment strategies, has become an urgent medical challenge. Currently, the heterogeneity of thyroid cancer makes it difficult for traditional preclinical models (such as two-dimensional cell lines and mouse models) to accurately reflect the biological characteristics of the tumor, limiting the progress of drug screening and personalized treatment for thyroid cancer.
[0003] The rise of organoid technology has provided a completely new modeling system for tumor research. An organoid is a three-dimensional in vitro cultured structure derived from stem cells or tumor cells, capable of mimicking the complexity and heterogeneity of in vivo tissues while maintaining the gene expression profile and mutational characteristics of the original tissue. This makes organoids an important tool for studying tumor biology, screening drugs, and achieving personalized treatment.
[0004] Currently, organoid culture technologies for various organs, such as the intestines, lungs, and liver, are relatively mature and have been successfully applied in disease research. However, research on organoid culture for thyroid cancer is still in its early stages. Due to the unique characteristics of thyroid tissue, establishing a stable and efficient organoid culture system for thyroid cancer remains a challenging issue. Existing methods for thyroid cancer organoid culture suffer from the following problems: 1. Incomplete culture medium composition: Most existing culture media are general-purpose and lack specific nutrients and growth factors for thyroid cancer cells, resulting in slow cell growth or abnormal differentiation.
[0005] 2. Low culture efficiency: Traditional culture media require more than 2 weeks to form stable organoids, and the activity decreases significantly after passage.
[0006] 3. Insufficient standardization of culture methods: Microenvironmental factors such as temperature, pH, and oxygen concentration have a significant impact on organoid formation. Existing methods do not allow for precise control, which affects the stability and reproducibility of the culture.
[0007] 4. For samples with low cell counts, such as pleural effusion samples, existing culture media and methods cannot achieve efficient amplification and culture of highly active organoids.
[0008] 5. Existing culture media and methods are not entirely suitable for all different pathological types of thyroid cancer. Developing culture media and optimized culture methods specifically for thyroid cancer will not only help deepen our understanding of this cancer, but also provide personalized model support for clinical treatment. Summary of the Invention
[0009] In order to solve the above-mentioned problems in the prior art, the purpose of this invention is to provide a culture medium for thyroid cancer organoids, its preparation method and uses, and a method for culturing thyroid cancer organoids.
[0010] To achieve the above objectives, the present invention adopts the following technical solution: This invention provides a culture medium for thyroid cancer organoids, comprising a basal culture medium and a specific additive factor, wherein the specific additive factor comprises components at the following final concentrations: 0.1~50 mmol / L HEPES; 0.1~20 mmol / L GlutaMAX; 50~200 IU / mL P / S; 0.1X~10XN2; 0.1X~10X B-27; 10~100 ng / mL EGF; 50~250 ng / mL FGF basic; 100~300 ng / mL FGF10; 100~300 ng / mL HGF; 20~200 ng / mL IGF; 10~100 ng / mL Wnt3a; 20~200 ng / mL R-spondin-1; 0.1~50 μmol / L A83-01; 0.2~60 μmol / L GSK429286A; 20~200 ng / mL Noggin; 0.1~50 μmol / L BIRB 796;0.1~50 mmol / L Nicotinamide; 0.1~20 mmol / L N-acetyl-L-cysteine; 5~200 nmol / L Monensin; 1~5 μmol / L P5091; 2~10 μmol / L A35.
[0011] Furthermore, the basal culture medium is DMEM / F12 medium.
[0012] Furthermore, the specific additive factor comprises components at the following final concentrations: 0.1~50 mmol / L HEPES; 0.1~20 mmol / L GlutaMAX; 50~200 IU / mL P / S; 0.1X~10XN2; 0.1X~10X B-27; 10~100 ng / mL EGF; 50~250 ng / mL FGF basic; 100~300 ng / mL FGF10; 100~300 ng / mL HGF; 20~200 ng / mL IGF; 10~100 ng / mL Wnt3a; 20~200 ng / mL R-spondin-1; 0.1~50 μmol / L A83-01; 0.2~60 μmol / L GSK429286A; 20~200 ng / mL Noggin; 0.1~50 μmol / L BIRB 796;0.1~50 mmol / L Nicotinamide; 0.1~20 mmol / L N-acetyl-L-cysteine; 10~50 nmol / L Monensin; 2.5~5 μmol / L P5091; 2.5~5 μmol / L A35.
[0013] Further, the specific additive factors comprise the following components at final concentrations: 10 mmol / L HEPES; 2 mmol / L GlutaMAX; 100 IU / mL P / S; 1X N2; 1X B-27; 50 ng / mL EGF; 150 ng / mL FGF basic; 200 ng / mL FGF10; 200 ng / mL HGF; 100 ng / mL IGF; 50 ng / mL Wnt3a; 100 ng / mL R-spondin-1; 10 μmol / L A83-01; 5~20 μmol / L GSK429286A; 100 ng / mL Noggin; 10 μmol / L BIRB 796; 10 mmol / L nicotinamide; 1.5 mmol / L N-acetyl-L-cysteine; 10~50 nmol / L Monensin; 2.5~5 μmol / L P5091; 2.5~5 μmol / L A35.
[0014] Furthermore, the specific additive factor comprises components at the following final concentrations: 10 mmol / L HEPES; 2 mmol / L GlutaMAX; 100 IU / mL P / S; 1X N2; 1X B-27; 50 ng / mL EGF; 150 ng / mL FGF basic; 200 ng / mL FGF10; 200 ng / mL HGF; 100 ng / mL IGF; 50 ng / mL Wnt3a; 100 ng / mL R-spondin-1; 10 μmol / L A83-01; 20 μmol / L GSK429286A; 100 ng / mL Noggin; 10 μmol / L BIRB 796; 10 mmol / L nicotinamide; 1.5 mmol / L N-acetyl-L-cysteine; 50nmol / L Monensin; 5 μmol / L P5091; 5 μmol / L A35.
[0015] The present invention also provides a method for preparing the above-mentioned thyroid cancer organoid culture medium, wherein the method comprises adding a specific additive factor to the basal culture medium and mixing it evenly to obtain the culture medium.
[0016] The present invention also provides a method for culturing thyroid cancer organoids, the method comprising the following steps: (1) Remove non-tumor components from fresh surgical excision specimens or core needle aspiration tissue to obtain the target tissue; (2) Cut the target tissue into tissue fragments of 1-3 mm; (3) Digest the tissue fragments with digestive fluid; (4) Filter and collect the filtrate; (5) Centrifuge to remove the supernatant, and resuspend the cells in matrix gel to obtain the matrix gel cell mixture; (6) Spread the matrix gel cell mixture on a culture dish, incubate, and form a gel; (7) Add the above-mentioned thyroid cancer organoid culture medium to the culture dish, change the culture medium every 2 to 5 days, and culture for 3 to 10 days to obtain thyroid cancer organoids.
[0017] Furthermore, the surgical resection specimen or core needle biopsy tissue described in step (1) is taken from a thyroid cancer patient; The digestive fluid in step (3) is at least one of trypsin or collagenase; The incubation conditions described in step (6) are 20~40℃, 1~10% CO2, 10~60 minutes; The time interval for changing the culture medium in step (7) is once every 3 days, and the actual culture time is 7 days.
[0018] Further, the thyroid cancer mentioned in step (1) is papillary thyroid carcinoma, follicular thyroid carcinoma, medullary thyroid carcinoma, poorly differentiated thyroid carcinoma, undifferentiated thyroid carcinoma, or sarcomatoid thyroid carcinoma; The digestive fluid mentioned in step (3) is collagenase; The incubation conditions described in step (6) are 37°C, 5% CO2, for 20-30 minutes.
[0019] The present invention also provides the use of the above-mentioned thyroid cancer organoid culture medium in culturing thyroid cancer organoids.
[0020] Furthermore, the thyroid cancer is papillary thyroid carcinoma, follicular thyroid carcinoma, medullary thyroid carcinoma, poorly differentiated thyroid carcinoma, undifferentiated thyroid carcinoma, or thyroid sarcomatoid carcinoma.
[0021] Furthermore, the intended use is for studying the mechanisms of thyroid cancer and screening drugs.
[0022] The present invention has achieved the following beneficial effects: This invention provides a thyroid cancer organoid culture medium, comprising a basal medium DMEM / F12 and specifically added factors HEPES, GlutaMAX, P / S, N2, B-27, EGF, FGF basic, FGF10, HGF, IGF, Wnt3a, R-spondin-1, A83-01, GSK429286A, Noggin, BIRB 796, nicotinamide, and N-acetyl-L-cysteine, Monensin, P5091, and A35.
[0023] The thyroid cancer organoid culture medium of the present invention has the following advantages: 1. Optimize the composition and concentration of existing thyroid cancer organoid culture media on the market.
[0024] 2. Improve the efficiency of thyroid cancer organoid culture.
[0025] 3. Standardized thyroid cancer organoid culture method.
[0026] 4. Highly active thyroid cancer organoids can be efficiently cultured using samples of trace cells.
[0027] 5. Suitable for the culture of low cell count samples (such as pleural effusion samples) and thyroid cancer organoids of various pathological types.
[0028] 6. Compared with the culture media disclosed in the prior art CN114891748A and CN112831471A, the culture medium of the present invention produces thyroid cancer organoids with denser spheroids, higher spheroid formation rate, larger spheroid size range, coexistence of mature large spheroids and newly formed small spheroids, sharp edges of most spheroids, dense interior, strong refractive properties, clean background, and less necrotic / detached debris.
[0029] In summary, the components of the thyroid cancer organoid culture medium of this invention work synergistically to promote cell proliferation, growth, and self-assembly. The method for culturing thyroid cancer organoids using the thyroid cancer organoid culture medium provided by this invention has the advantages of requiring fewer sample cells, a shorter culture period, rapid proliferation, a large number of cells, high survival rate, and applicability to various pathological types of thyroid cancer. It provides a new strategy for thyroid cancer mechanism research, drug screening, and personalized treatment, and has excellent application prospects.
[0030] Obviously, based on the above description of the present invention, and according to common technical knowledge and conventional methods in the field, various other modifications, substitutions or alterations can be made without departing from the basic technical concept of the present invention.
[0031] The following detailed embodiments further illustrate the above-described content of the present invention. However, this should not be construed as limiting the scope of the present invention to the following examples. All technologies implemented based on the above-described content of the present invention fall within the scope of the present invention. Attached Figure Description
[0032] Figure 1 The thyroid carcinoma organoids obtained in Example 1 (A) and Comparative Example 1 (B) are examples of thyroid carcinoma organoids.
[0033] Figure 2 The thyroid carcinoma organoids obtained in Example 2 (A) and Comparative Example 2 (B) are examples of thyroid carcinoma organoids.
[0034] Figure 3 The thyroid carcinoma organoids obtained in Example 3 (A) and Comparative Example 3 (B) are examples of thyroid carcinoma organoids.
[0035] Figure 4 The organoid for thyroid cancer obtained in Example 4.
[0036] Figure 5 The organoid for thyroid cancer obtained in Comparative Example 4.
[0037] Figure 6 The organoid for thyroid cancer obtained in Example 5.
[0038] Figure 7 The organoid for thyroid cancer obtained in Example 6.
[0039] Figure 8 The organoid for thyroid cancer obtained in Example 7.
[0040] Figure 9 The organoid for thyroid cancer obtained in Example 8.
[0041] Figure 10 The organoid for thyroid cancer obtained in Example 9.
[0042] Figure 11 The organoid for thyroid cancer obtained in Example 10.
[0043] Figure 12 The organoid for thyroid cancer obtained in Comparative Example 5.
[0044] Figure 13 The organoid for thyroid cancer obtained in Comparative Example 6. Detailed Implementation
[0045] The raw materials and equipment used in this invention are all known products, obtained by purchasing commercially available products.
[0046] The following experiments, where no temperature is specified, are reactions conducted under normal temperature conditions, which is room temperature, or 25±5℃.
[0047] In the following culture medium formulations, 1X N2 indicates that the final concentration of N2 in the culture medium is the standard usage concentration, and 1X B-27 indicates that the final concentration of B-27 in the culture medium is the standard usage concentration.
[0048] The specific additive factors involved in the specific embodiments of the present invention are as follows: HEPES is 4-hydroxyethylpiperazine ethanesulfonic acid; GlutaMAX is L-alanyl-glutamine; P / S is penicillin / streptomycin; N2 is N2 supplement; B-27 is B-27 supplement; EGF is epidermal growth factor; FGF basic is basal fibroblast growth factor; FGF10 is fibroblast growth factor 10; HGF is hepatocyte growth factor; IGF is insulin-like growth factor; Wnt3a is Wnt3a protein; R-spondin-1 is R-spondin-1 protein; A83-01 is a TGF-β receptor inhibitor; GSK429286A is a ROCK inhibitor; Noggin is Noggin protein; BIRB 796 is a p38 MAPK inhibitor. 796; Monensin is a small molecule ion channel; P5091 is a USP7 deubiquitinase inhibitor; P5091 and A35 are small molecule ligands of TSHR, A35.
[0049] Example 1: The method for culturing thyroid cancer organoids includes the following steps: 1) Fresh surgical specimens of thyroid cancer were transported to the laboratory at 4°C within 2 hours after being removed from the body, and non-tumor components such as fat were removed from the tissue using dissecting scissors and forceps.
[0050] 2) Add digestive fluid to the thyroid cancer tissue obtained in the previous step and digest for about 15 minutes.
[0051] 3) Filter the digested thyroid cancer tissue through a 100 μm cell filter, collect the filtered thyroid cancer cells, and centrifuge at 500g for 5 minutes.
[0052] 4) Remove the supernatant, resuspend the thyroid cancer cells in matrix gel, and mix thoroughly by pipetting.
[0053] 5) Drop the matrix gel containing thyroid cancer cells obtained in the previous step into a preheated 24-well plate, one drop per well, approximately 50 µL.
[0054] 6) Place the culture plate in an incubator at 37°C and 5% CO2 for 20-30 minutes to allow the droplets to solidify.
[0055] 7) Add thyroid cancer organoid culture medium 1 to the culture dish, change the culture medium every 3 days, and after 7 days of culture, the obtained thyroid cancer organoids are as follows: Figure 1 As shown in Figure A.
[0056] The thyroid cancer organoid culture medium 1 mentioned above includes a basal culture medium and specific additives, wherein the specific additives include components with final concentrations as shown in Table 1.
[0057] Example 2: The thyroid cancer organoid culture method in Example 1 is the same as that in step 7), except that the thyroid cancer organoid culture medium 1 is replaced with thyroid cancer organoid culture medium 2.
[0058] The culture medium was changed every 3 days. After 7 days of culture, thyroid cancer organoids were obtained, such as... Figure 2 As shown in Figure A.
[0059] The thyroid cancer organoid culture medium 2 mentioned above includes a basal culture medium and specific additives, wherein the specific additives include components with final concentrations as shown in Table 1.
[0060] Example 3: The thyroid cancer organoid culture method in Example 1 is the same as that in step 7), except that the thyroid cancer organoid culture medium 1 is replaced with thyroid cancer organoid culture medium 3.
[0061] The culture medium was changed every 3 days. After 7 days of culture, thyroid cancer organoids were obtained, such as... Figure 3 As shown in Figure A.
[0062] The thyroid cancer organoid culture medium 3 mentioned above includes a basal culture medium and specific additives, wherein the specific additives include components with final concentrations as shown in Table 1.
[0063] Example 4: The thyroid cancer organoid culture method in Example 1 is the same as that in step 7), except that the thyroid cancer organoid culture medium 1 is replaced with the thyroid cancer organoid culture medium 4.
[0064] The culture medium was changed every 3 days. After 7 days of culture, thyroid cancer organoids were obtained, such as... Figure 4 As shown.
[0065] The thyroid cancer organoid culture medium 4 mentioned above includes a basal culture medium and specific additives, wherein the specific additives include components with final concentrations as shown in Table 1.
[0066] Example 5: The thyroid cancer organoid culture method in Example 4 is the same, except that the surgical resection specimen of thyroid cancer in step 1) is replaced with the surgical resection specimen of papillary thyroid carcinoma.
[0067] The culture medium was changed every 3 days. After 7 days of culture, thyroid cancer organoids were obtained, such as... Figure 6 As shown.
[0068] Example 6: The thyroid cancer organoid culture method in Example 4 is the same as that in step 1), except that the surgical resection specimen of thyroid cancer is replaced with the surgical resection specimen of thyroid follicular carcinoma.
[0069] The culture medium was changed every 3 days. After 7 days of culture, thyroid cancer organoids were obtained, such as... Figure 7 As shown.
[0070] Example 7: The thyroid cancer organoid culture method in Example 4 is the same as that in step 1), except that the surgical resection specimen of thyroid cancer is replaced with the surgical resection specimen of medullary thyroid carcinoma.
[0071] The culture medium was changed every 3 days. After 7 days of culture, thyroid cancer organoids were obtained, such as... Figure 8 As shown.
[0072] Example 8: The thyroid cancer organoid culture method in Example 4 is the same as that in step 1), except that the surgical resection specimen of thyroid cancer is replaced with the surgical resection specimen of poorly differentiated thyroid cancer.
[0073] The culture medium was changed every 3 days. After 7 days of culture, thyroid cancer organoids were obtained, such as... Figure 9 As shown.
[0074] Example 9: The thyroid cancer organoid culture method is the same as in Example 4, except that the surgical resection specimen of thyroid cancer in step 1) is replaced with the surgical resection specimen of thyroid sarcomatoid carcinoma.
[0075] The culture medium was changed every 3 days. After 7 days of culture, thyroid cancer organoids were obtained, such as... Figure 10 As shown.
[0076] Example 10: The thyroid cancer organoid culture method in Example 4 is the same, except that the surgical resection specimen of thyroid cancer in step 1) is replaced with the surgical resection specimen of undifferentiated thyroid carcinoma.
[0077] The culture medium was changed every 3 days. After 7 days of culture, thyroid cancer organoids were obtained, such as... Figure 11 As shown.
[0078] Table 1. Composition of culture media for different thyroid cancer organoids The diagonal border in the table above indicates that this component was not added.
[0079] The following is a comparative preparation method of the present invention.
[0080] Comparative Example 1: The thyroid cancer organoid culture method in Example 1 is the same as that in step 7), except that the thyroid cancer organoid culture medium 1 is replaced with the thyroid cancer organoid culture medium 5.
[0081] The culture medium was changed every 3 days. After 7 days of culture, thyroid cancer organoids were obtained, such as... Figure 1 As shown in B.
[0082] The thyroid cancer organoid culture medium 5 mentioned above includes a basal culture medium and specific additives, wherein the specific additives include components with final concentrations as shown in Table 1.
[0083] Comparative Example 2: The thyroid cancer organoid culture method in Example 1 is the same as that in step 7), except that the thyroid cancer organoid culture medium 1 is replaced with the thyroid cancer organoid culture medium 6.
[0084] The culture medium was changed every 3 days. After 7 days of culture, thyroid cancer organoids were obtained, such as... Figure 2 As shown in B.
[0085] The thyroid cancer organoid culture medium 6 mentioned above includes a basal culture medium and specific additives, wherein the specific additives include components with final concentrations as shown in Table 1.
[0086] Comparative Example 3: The thyroid cancer organoid culture method in Example 1 is the same as that in step 7), except that the thyroid cancer organoid culture medium 1 is replaced with thyroid cancer organoid culture medium 7.
[0087] The culture medium was changed every 3 days. After 7 days of culture, thyroid cancer organoids were obtained, such as... Figure 3 As shown in B.
[0088] The thyroid cancer organoid culture medium 7 mentioned above includes a basal culture medium and specific additives, wherein the specific additives include components with final concentrations as shown in Table 1.
[0089] Comparative Example 4: The thyroid cancer organoid culture method in Example 4 is the same as that in step 1), except that the surgical resection specimen of thyroid cancer is replaced with pleural effusion specimen of thyroid cancer metastasis.
[0090] The culture medium was changed every 3 days. After 7 days of culture, thyroid cancer organoids were obtained, such as... Figure 5 As shown.
[0091] Comparative Example 5: The thyroid cancer organoid culture method in Example 1 is the same as that in step 7), except that the thyroid cancer organoid culture medium 4 is replaced with thyroid cancer organoid culture medium 8 (from Example 1 of CN112831471A). Figure 12 .
[0092] The thyroid cancer organoid culture medium 8 mentioned above includes a basal culture medium and specific additives, wherein the specific additives include components with final concentrations as shown in Table 2.
[0093] Table 2 shows the final concentrations of components in the thyroid cancer organoid culture medium (8). Comparative Example 6: The thyroid cancer organoid culture method in Example 1 is the same as that in step 7), except that the thyroid cancer organoid culture medium 4 is replaced with thyroid cancer organoid culture medium 9 (from Example 4 of CN114891748A). Figure 13 .
[0094] The thyroid cancer organoid culture medium 9 mentioned above includes a basal culture medium and specific additives, wherein the specific additives include components with final concentrations as shown in Table 3.
[0095] Table 3 shows the final concentrations of components in the thyroid cancer organoid culture medium. Comparing the thyroid cancer organoids obtained according to the methods of Examples 1-10 and Comparative Examples 1-6, the following conclusions can be drawn: (1) Combining formula variables and Figure 1 Imaging results show that there are multi-component synergistic differences in the culture media of Example 1 and Comparative Example 1. These differences involve not only changes in the Monensin concentration gradient but also variations in the ratios of multiple key regulatory factors such as GSK429286A, P5091, and A35. This indicates a multivariate combined modification system, and therefore cannot be attributed solely to the functional effect of Monensin. However, overall comparison shows that the thyroid cancer organoids cultured with the complete formulation in Example 1 are more robust, proliferate faster, and have a denser structure. In contrast, the organoids in the formulation group of Comparative Example 1 are smaller, grow more slowly, and have lower organoid formation efficiency. This confirms that the optimized multi-factor combination system of this invention is an important foundation for ensuring the normal growth and self-assembly of thyroid cancer organoids. The absence or reduction of key small molecule ratios significantly inhibits organoid growth activity.
[0096] (2) Example 2 and Comparative Example 2 also showed differences in multiple component variables. Besides the change in P5091 concentration, the proportions of Monensin, GSK429286A, and other components also differed, making it impossible to independently verify the role of P5091. From Figure 2 Morphological comparison revealed that the optimized formulation system in Example 2 produced a greater number of organoids with more uniform morphology and less apoptosis; while the composition in Comparative Example 2 showed a decrease in the number of viable cells, some cells exhibited vacuolation and apoptosis signs, and the organoid budding and proliferation capacity was weakened. The results confirm that the optimized component combination with P5091 as its core can effectively maintain the activity of thyroid cancer cells, inhibit apoptosis, and enhance organoid proliferation capacity; the absence of this component significantly reduces the stability of the culture system.
[0097] (3) The formulations in Example 3 and Comparative Example 3 involve the combined adjustment of A35 concentration and multiple supporting factors, and are not single-variable controls. Figure 3 The results showed that the organoids in the Example 3 system proliferated vigorously, were numerous, and had a high formation rate; while the organoids in the Comparative Example 3 system grew slowly, formed sparsely, and were smaller in size. This verified that the specific additive factor combination containing A35 can effectively activate the proliferation of thyroid cancer cells and improve the in vitro microenvironment, making it a key component for the efficient construction of thyroid cancer organoids.
[0098] (4) Comparative Example 4 ( Figure 5 Using pleural effusion specimens from metastatic thyroid cancer, and in Example 4 ( Figure 4Compared with thyroid cancer surgical specimens, this method also cultured rapidly proliferating and large-sized thyroid cancer organoids, indicating that it is also applicable to tissues with fewer thyroid cancer cell sources.
[0099] (5) In Examples 5-10, papillary thyroid carcinoma, follicular thyroid carcinoma, medullary thyroid carcinoma, poorly differentiated thyroid carcinoma, sarcomatoid thyroid carcinoma, and undifferentiated thyroid carcinoma were used as samples for organoid culture. The thyroid cancer organoids obtained according to the methods in Examples 5-10 are as follows: Figure 6-11 As shown in the figure. The results indicate that all examples 5-10 successfully cultured rapidly proliferating, large-volume thyroid cancer organoid specimens, demonstrating that the culture medium components and methods are suitable for different pathological types of thyroid cancer. The aforementioned different pathological types of thyroid cancer specifically include: papillary thyroid carcinoma, follicular thyroid carcinoma, medullary thyroid carcinoma, poorly differentiated thyroid carcinoma, and undifferentiated carcinoma (undifferentiated thyroid carcinoma, thyroid sarcomatoid carcinoma).
[0100] (6) Comparative Example 1 ( Figure 1 A) Comparative Example 5 Figure 12 Comparative Example 6 Figure 13 The thyroid cancer organoids obtained are shown in Table 4.
[0101] Table 4. Example 1 ( Figure 1 A) Comparative Example 5 Figure 12 Comparative Example 6 Figure 13 Comparison of thyroid cancer organoids obtained In summary, this invention provides a thyroid cancer organoid culture medium, comprising a basal medium DMEM / F12 and specific additives including HEPES, GlutaMAX, P / S, N2, B-27, EGF, FGF basic, FGF10, HGF, IGF, Wnt3a, R-spondin-1, A83-01, GSK429286A, Noggin, BIRB 796, Monensin, P5091, A35, nicotinamide, and N-acetyl-L-cysteine. The components of this thyroid cancer organoid culture medium work synergistically to promote cell proliferation, growth, and self-assembly. The method for culturing thyroid cancer organoids using the culture medium provided by this invention has advantages such as requiring fewer sample cells, a shorter culture period, rapid proliferation, a large number of cells, high survival rate, and applicability to various pathological types of thyroid cancer. It provides a new strategy for thyroid cancer mechanism research, drug screening, and personalized treatment, and has excellent application prospects.
Claims
1. A culture medium for thyroid cancer organoids, characterized in that, It includes a basal culture medium and a specific additive factor, wherein the specific additive factor comprises components at the following final concentrations: 10 mmol / L HEPES; 2 mmol / L GlutaMAX; 100 IU / mL P / S; 1X N2; 1X B-27; 50 ng / mLEGF; 150 ng / mL FGF basic; 200 ng / mL FGF10; 200 ng / mL HGF; 100 ng / mL IGF; 50 ng / mLWnt3a; 100 ng / mL R-spondin-1; 10 μmol / L A83-01; 5~20 μmol / L GSK429286A; 100 ng / mLNoggin; 10 μmol / L BIRB 796; 10 mmol / L nicotinamide; 1.5 mmol / L N-acetyl-L-cysteine; 10~50nmol / L Monensin; 2.5~5 μmol / L P5091; 2.5~5 μmol / L A35.
2. The thyroid cancer organoid culture medium according to claim 1, characterized in that, The basal culture medium is DMEM / F12 medium.
3. The thyroid cancer organoid culture medium according to claim 1, characterized in that, The specific additive factor comprises components at the following final concentrations: 10 mmol / L HEPES; 2 mmol / L GlutaMAX; 100 IU / mL P / S; 1X N2; 1X B-27; 50 ng / mLEGF; 150 ng / mL FGF basic; 200 ng / mL FGF10; 200 ng / mL HGF; 100 ng / mL IGF; 50 ng / mLWnt3a; 100 ng / mL R-spondin-1; 10 μmol / L A83-01; 20 μmol / L GSK429286A; 100 ng / mL Noggin; 10 μmol / L BIRB 796; 10 mmol / L nicotinamide; 1.5 mmol / L N-acetyl-L-cysteine; 50nmol / L Monensin; 5 μmol / L P5091; 5 μmol / L A35.
4. A method for preparing the thyroid cancer organoid culture medium according to any one of claims 1-3, characterized in that, The method involves adding a specific additive factor to the basal culture medium and mixing it thoroughly.
5. A method for culturing thyroid cancer organoids, characterized in that, The cultivation method includes the following steps: (1) Remove non-tumor components from fresh surgical excision specimens or core needle aspiration tissue to obtain the target tissue; (2) Cut the target tissue into tissue fragments of 1-3 mm; (3) Digest the tissue fragments with digestive fluid; (4) Filter and collect the filtrate; (5) Centrifuge to remove the supernatant, and resuspend the cells in matrix gel to obtain the matrix gel cell mixture; (6) Spread the matrix gel cell mixture on a culture dish, incubate, and form a gel; (7) Add the thyroid cancer organoid culture medium according to any one of claims 1 to 3 to the culture dish, change the culture medium every 2 to 5 days, and culture for 3 to 10 days to obtain thyroid cancer organoids.
6. The cultivation method according to claim 5, characterized in that, The surgical specimen or core needle biopsy tissue described in step (1) was obtained from a thyroid cancer patient; The digestive fluid in step (3) is at least one of trypsin or collagenase; The incubation conditions described in step (6) are 20~40℃, 1~10% CO2, 10~60 minutes; The time interval for changing the culture medium in step (7) is once every 3 days, and the culture time is 7 days.
7. The cultivation method according to claim 6, characterized in that, The thyroid cancer mentioned in step (1) is papillary thyroid carcinoma, follicular thyroid carcinoma, medullary thyroid carcinoma, poorly differentiated thyroid carcinoma, undifferentiated thyroid carcinoma, or sarcomatoid thyroid carcinoma; The digestive fluid mentioned in step (3) is collagenase; The incubation conditions described in step (6) are 37°C, 5% CO2, for 20-30 minutes.
8. Use of the thyroid cancer organoid culture medium according to any one of claims 1-3 in culturing thyroid cancer organoids.
9. The use according to claim 8, characterized in that, The thyroid cancer mentioned refers to papillary thyroid carcinoma, follicular thyroid carcinoma, medullary thyroid carcinoma, poorly differentiated thyroid carcinoma, undifferentiated thyroid carcinoma, or thyroid sarcomatoid carcinoma.
10. The use according to claim 8, characterized in that, The stated purpose is to conduct mechanistic studies of thyroid cancer and to screen drugs.
Citation Information
Patent Citations
Culture medium, culture method and detection method of thyroid cancer organoid
CN112831471A
Culture medium of thyroid cancer organoid and culture method of thyroid cancer organoid
CN114891748A
